15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering LeMaitre Vascular Inc, 3 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $95.00 to $127.00, so the covering firms are broadly aligned. The average target of $112.60 sits 10% above the current $102.30. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.73 next quarter toward $3.26 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy360%
Hold240%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to LeMaitre Vascular Inc.
As of Jul, 3 of 5 firms rate LMAT a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
LMAT EPS & revenue forecast
EPS · NEXT QUARTER
$0.73
Range $0.69 – $0.77 · 9 analysts · -2% YoY
Next period, 9 analysts expect LeMaitre Vascular Inc to earn $0.73 a share (range $0.69 – $0.77), versus $0.75 a year earlier. Full-year consensus is $3.00, growing to $3.26 the year after.
REVENUE · NEXT QUARTER
$69.2M
Range $67.9M – $70.3M · 9 analysts · +13% YoY
Revenue is expected to reach $69.2M (range $67.9M – $70.3M), +13.3% year-over-year. Full-year consensus is $280.0M, rising to $305.8M next year.
Top analysts covering LeMaitre Vascular Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LMAT.
#1
Ross Osborn
Cantor Fitzgerald · Rank #139
Hold
$95.00-7.1% to target
Overall win rate
34%
+ Follow
#2
Michael Petusky
Barrington Research · Rank #322
Buy
$120.00+17.3% to target
Overall win rate
29%
+ Follow
#3
Frank Takkinen
Lake Street · Rank #327
Buy
$135.00+32.0% to target
Overall win rate
26%
+ Follow
#4
NT
Nathan Treybeck
Wells Fargo
Hold
$104.00+1.7% to target
Coverage
—
+ Follow
#5
KB
Kyle Bauser
Roth Capital
Buy
$117.00+14.4% to target
Coverage
—
+ Follow
LMAT stock forecast FAQ
What is LMAT's average 12-month price target?+
The 5 analysts with a live target average $112.60 for LeMaitre Vascular Inc over the next 12 months, ranging from a $127.00 high to a $95.00 low.
Is LMAT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 3 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for LMAT?+
The Street-high target is $127.00 (Citizens), and the Street-low is $95.00 (Cantor Fitzgerald). The average of all 5 active targets is $112.60.
How many Wall Street analysts cover LMAT?+
5 analysts have an active rating on LeMaitre Vascular Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering LMAT?+
Among analysts who currently cover LMAT, Ross Osborn of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #139). Their current call is Hold with a $95.00 target.
What is LeMaitre Vascular Inc's projected EPS for next quarter?+
The consensus estimate is $0.73 per share (range $0.69 – $0.77) across 9 analysts. Full-year EPS is projected at $3.00, rising to $3.26 the following year.
How much revenue is LeMaitre Vascular Inc expected to report next quarter?+
Consensus revenue is $69.2M (range $67.9M – $70.3M). Full-year revenue is projected at $280.0M, growing to $305.8M next year.
Have analysts been upgrading or downgrading LMAT lately?+
As of Jul, 3 of 5 firms rate LMAT a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LMAT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
